drugset / Trial / NCT03406819
Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI
Unknown
1000 enrolled
The First Affiliated Hospital of Zhengzhou University
Anyang Regional Hospital · collabChinese Academy of Medical Sciences, Fuwai Hospital · collabFirst Affiliated Hospital of Xinjiang Medical University · collabHuaihe Hospital of Henan University · collabJincheng People's Hospital · collabKaifeng Central Hospital · collabLushan People's Hospital · collabNanyang Central Hospital · collabPeople's Hospital of Zhengzhou University · collabPuyang Oilfield General Hospital · collabPuyang People's Hospital · collabShenma Medical Group General Hospital · collabThe 99th Central Hospital of the People's Liberation Army · collabThe First Affiliated Hospital of Henan University of Science and Technology · collabThe First People's Hospital of Shangqiu · collabThe First People's Hospital of Xinmi · collabThe First People's Hospital of Zhumadian · collabThe Peoples' Hospital of Jiaozuo City · collabThe Second People's Hospital of Pingdingshan · collabThe second people's Hospital of Jiyuan · collabXinyang Central Hospital · collabYanshi People's Hospital · collabYellow River Sanmenxia hospital · collabZhengzhou Central Hospital · collabZhengzhou First People's Hospital · collabZhoukou Central Hospital · collabZhumadian Central Hospital · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Primary percutaneous coronary intervention (PPCI) is the gold standard of treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following PPCI in STEMI patients has been a serious and common complication that closely related to the incidence of major adverse cardiovascular events (MACE) and affected patients' prognosis. No reflow is a multi-factorial phenomenon. And its preventive and therapeutic effects are not satisfactory. This prospective randomized controlled study aimed to compare favorable effects of Nitroprusside versus Tirofiban on the prevention of slow flow / no-reflow phenomenon during PPCI.
Timeline
- Start
- 2018-01-07
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nitroprusside Sodium | Unknown | 50 ug | Other |
| Subject | Nitroprusside Sodium | Unknown | 100 ug | Other |
| Subject | Tirofiban | Other / unclassified | 10 ug/kg | Other |